FNY Investment Advisers LLC Buys Shares of 2,000 The Chemours Company (NYSE:CC)

FNY Investment Advisers LLC purchased a new position in The Chemours Company (NYSE:CC) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,000 shares of the specialty chemicals company’s stock, valued at approximately $27,000.

Several other institutional investors have also added to or reduced their stakes in CC. Strategic Financial Concepts LLC acquired a new stake in Chemours in the fourth quarter worth about $357,000. State of New Jersey Common Pension Fund D boosted its holdings in Chemours by 9.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 111,361 shares of the specialty chemicals company’s stock worth $1,882,000 after acquiring an additional 9,691 shares in the last quarter. Peregrine Capital Management LLC acquired a new stake in Chemours in the fourth quarter worth about $5,731,000. Y Intercept Hong Kong Ltd acquired a new stake in Chemours in the fourth quarter worth about $996,000. Finally, Amalgamated Bank boosted its holdings in Chemours by 4.6% in the fourth quarter. Amalgamated Bank now owns 72,714 shares of the specialty chemicals company’s stock worth $1,229,000 after acquiring an additional 3,188 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Insider Buying and Selling at Chemours

In other Chemours news, insider Damian Gumpel bought 7,822 shares of the firm’s stock in a transaction dated Tuesday, June 3rd. The shares were purchased at an average price of $9.95 per share, for a total transaction of $77,828.90. Following the transaction, the insider now directly owns 131,701 shares of the company’s stock, valued at approximately $1,310,424.95. This represents a 6.31% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Shane Hostetter bought 4,450 shares of the firm’s stock in a transaction dated Monday, May 19th. The shares were acquired at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the transaction, the chief financial officer now directly owns 59,694 shares in the company, valued at approximately $673,348.32. This represents a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 25,672 shares of company stock valued at $251,573. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Chemours from a “hold” rating to a “sell” rating in a report on Wednesday, May 21st. Truist Financial decreased their target price on Chemours from $27.00 to $22.00 and set a “buy” rating for the company in a report on Monday, April 14th. Morgan Stanley decreased their target price on Chemours from $22.00 to $15.00 and set an “equal weight” rating for the company in a report on Monday, May 12th. The Goldman Sachs Group decreased their target price on Chemours from $21.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 14th. Finally, Royal Bank Of Canada decreased their target price on Chemours from $17.00 to $14.00 and set an “outperform” rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Chemours currently has a consensus rating of “Hold” and a consensus target price of $17.22.

Chemours Trading Down 1.5%

Shares of NYSE:CC opened at $10.78 on Wednesday. The Chemours Company has a 12-month low of $9.13 and a 12-month high of $25.54. The company has a market capitalization of $1.61 billion, a PE ratio of 53.88 and a beta of 1.64. The business has a 50 day moving average of $11.25 and a two-hundred day moving average of $14.84. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01.

Chemours (NYSE:CC) last announced its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.06). Chemours had a net margin of 0.54% and a return on equity of 23.82%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The company’s revenue was up .4% compared to the same quarter last year. As a group, analysts forecast that The Chemours Company will post 2.03 EPS for the current year.

Chemours Announces Dividend

The business also recently declared a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were issued a $0.0875 dividend. This represents a yield of 3.17%. The ex-dividend date of this dividend was Friday, May 16th. Chemours’s payout ratio is presently 175.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.